

## CLAIMS

1. Sterile, liquid preparation in the form of an aqueous solution for the application as a solution for injection or as an aerosol containing about 80 mg/ml to 120 mg/ml of tobramycin and an acidic adjuvant, characterised in that the preparation contains not more than about 2 mg/ml of sodium chloride.
2. Preparation according to claim 1, wherein the preparation is essentially free of sodium chloride.
3. Preparation according to claim 2, wherein the preparation contains at least one essentially neutral isotonicising agent.
4. Preparation according to claim 3, wherein the isotonicising agent is a magnesium salt, a calcium salt, a sugar or a sugar alcohol.
5. Preparation according to one of the preceding claims, wherein the preparation has a pH of about 5.5 to about 6.5.
6. Preparation according to one of the preceding claims, wherein the acidic adjuvant is sulfuric acid or hydrochloric acid.
7. Preparation according to one of the preceding claims, wherein the preparation contains at least one surface active adjuvant.
8. Preparation according to claim 7, wherein the surface active adjuvant is a phospholipid.
9. Preparation according to claim 8, wherein the preparation contains tyloxapol as a further surface active adjuvant.
10. Preparation according to one of the preceding claims, wherein the preparation has a dynamic viscosity at room temperature of about 1.6 to 2.0 mPa·s and an osmolality of about 200 to 300 mOsmol/l.
11. Preparation according to one of the preceding claims, wherein the preparation has an osmolality of about 230 to 280 mOsmol/l.

12. Preparation according to one of the preceding claims, wherein the preparation exists as a measured single dose within a primary packaging.
13. Preparation according to claim 12, wherein the primary packaging is formed by a plastic container which comprises a removal closure element.
- 5 14. Preparation according to claim 13, wherein the removal of the closure element forms a round opening in the plastic container, the diameter of which corresponds to about the internal diameter of a female Luer lock adapter.
15. Preparation according to claim 13 or 14, wherein the plastic container, after removal of the closure element, can be fitted essentially tightly to the connector of a nebuliser which is provided for the input of liquid.
- 10 16. Preparation according to one of claims 13 to 15, wherein the plastic container is provided with at least one embossing, which represents a product designation, a lot code, a use-by date and/or a volume or dose marking.
- 15 17. Kit for the manufacture of a preparation according to one of the preceding claims, comprising (a) a liquid or solid component containing an active agent and (b) a liquid component which is free of active agent.
18. Use of a preparation according to one of claims 1 to 16 or of a kit according to claim 17 for the manufacture of a medicament for intravenous, intraarterial, subcutaneous or intramuscular injection.
- 20 19. Use of a preparation according to one of claims 1 to 16 or of a kit according to claim 17 for the manufacture of a medicament for the application in the form of an aerosol.
20. Use according to claim 19 or the pulmonary application by means of a jet, ultrasonic or piezoelectric nebuliser.
- 25 21. Use according to claim 20, wherein the piezoelectric nebuliser is a device of the eFlow™ type of PARI.
22. Use according to claim 21 for the nasal application by means of a mechanical atomiser or a jet, ultrasonic or piezoelectric nebuliser.
23. Use according to claim 22 for administration to the mucosa of the paranasal and/or frontal sinuses.

24. Use according to claim 22 for administration by means of a jet nebuliser which comprises a nose piece for supplying an aerosol to one or both nostrils of a patient and the aerosol output of which has a pulsating pressure.